|Application ||WB, IF, ICC, E|
|Other Accession||NP_002993, 9392|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||17043 Da|
|Application Notes||SDHD antibody can be used for detection of SDHD by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 2.5 μg/mL. For immunofluorescence start at 2.5 μg/mL.|
|Target/Specificity||SDHD antibody was raised against a 15 amino acid synthetic peptide near the center of human SDHD.|
The immunogen is located within amino acids 30 - 80 of SDHD.
|Reconstitution & Storage||SDHD antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||SDHD Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).|
|Cellular Location||Mitochondrion inner membrane; Multi-pass membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SDHD Antibody: The mitochondrial succinate dehydrogenase complex subunit D (SDHD) is one of four proteins that make up the tricarboxylic cycle enzyme succinate dehydrogenase (SCH). Studies have shown that mutations in SDHD often leads to hereditary paragangliomas, usually benign tumors of the autonomic nervous system, suggesting that SDHD also plays a role as a tumor-suppressor gene. In one family with a nonsense mutation (R22X) in the SDHD gene, a loss of heterozygosity was found in the paragangliomas, and within these tumors the enzymatic activity of Complex II in the mitochondrial respiratory chain was completely abolished. Furthermore, high levels of angiogenic factors EPAS1 and VEGF was observed, which may stimulate tumor growth.
Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848-51.
Saraste M. Oxidative phosphorylation at the fin de siecle. Science 1999; 283:1488-93.
Knudson AG. Genetics of human cancer. Annu. Rev. Genet. 1986; 20:231-51.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of Complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 2001; 69:1186-97.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.